Does the gut bacterial metabolite ImP directly cause increased Alzheimer’s pathology in humans?

Lens adapted to this topic: What human evidence can and cannot show

A more cautious reading separates human association from preclinical causation. The human data show that ImP tracks with cognitive and biomarker differences, but they do not show that exposure preceded or produced Alzheimer’s pathology. Reverse causation, confounding, and the limits of translating mouse and cell findings to humans remain important uncertainties.

• The human cohort findings remain associations and do not demonstrate that ImP causes Alzheimer’s disease or pathology.
• Differences in gut bacteria may partly reflect dementia-related changes in diet, chewing, activity, medication, or other factors, so causal direction is uncertain.
• The strongest mechanistic evidence comes from chronic exposure experiments in mice and in vitro human-cell studies, not from an intervention in humans.
• A genetic association can strengthen causal inference, but the cited evidence still does not directly test whether lowering ImP prevents or reverses Alzheimer’s pathology in people.

Featured sourceGut bacterial metabolite imidazole propionate potentiates Alzheimer’s disease pathology | Nature Communicationsnature.com4 sourcesView sources